Additional data presented at ASCO confirm the potential for synergistic combinations of Cavatak with immune checkpoint inhibitor (ICI) drugs to improve the proportion of cancer patients who respond to ICI therapy. Three Phase Ib trials are underway testing Cavatak in combination with Yervoy or Keytruda in melanoma, lung and bladder cancers. Initial data in April showed an impressive 67% response rate in the first six patients in the MITCI study of Cavatak and Yervoy in melanoma. Further updat
10 Jun 2016
Three Cavatak/checkpoint combination trials
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Three Cavatak/checkpoint combination trials
Viralytics (VLA:ASX) | 0 0 -4.6% | Mkt Cap: 175.3m
- Published:
10 Jun 2016 -
Author:
Dr Dennis Hulme -
Pages:
8
Additional data presented at ASCO confirm the potential for synergistic combinations of Cavatak with immune checkpoint inhibitor (ICI) drugs to improve the proportion of cancer patients who respond to ICI therapy. Three Phase Ib trials are underway testing Cavatak in combination with Yervoy or Keytruda in melanoma, lung and bladder cancers. Initial data in April showed an impressive 67% response rate in the first six patients in the MITCI study of Cavatak and Yervoy in melanoma. Further updat